UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Main results already published
Unique ID issued by UMIN UMIN000038155
Receipt No. R000043498
Scientific Title Comparison on the prevention of household influenza infection between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database -2018/2019 influenza season-
Date of disclosure of the study information 2019/10/01
Last modified on 2021/01/20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Comparison on the prevention of household influenza infection between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database -2018/2019 influenza season-
Acronym Comparison on the prevention of household influenza infection between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database
Scientific Title Comparison on the prevention of household influenza infection between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database -2018/2019 influenza season-
Scientific Title:Acronym Comparison on the prevention of household influenza infection between baloxavir marboxil and neuraminidase inhibitors using health insurance claims database
Region
Japan

Condition
Condition Influenza virus infection
Classification by specialty
Infectious disease
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To examine the preventive effect of baloxavir marboxil on household influenza infection compared with neuraminidase inhibitors in 2018/2019 influenza season. The primary comparison drug is oseltamivir.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Occurrence of household influenza infection
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1)Families which had an IC (index case; the first patient diagnosed as influenza in each family) during the enrollment period (1 Oct 2018 - 23 Apr 2019)
2)Families whose IC was an outpatient
3)Families whose IC received baloxavir marboxil, oseltamivir, zanamivir or laninamivir on Day 1 (the first date when an IC was diagnosed as influenza).
Key exclusion criteria 1)Families in which no family member was identified other than the IC
2)Families which had two or more ICs
3)Families whose IC was hospitalized after outpatient diagnosis
4)Families whose IC received several anti-influenza drugs
Target sample size 120000

Research contact person
Name of lead principal investigator
1st name Masaru
Middle name
Last name Sawada
Organization Shionogi & Co., Ltd.
Division name Pharmacovigilance Department
Zip code 541-0045
Address 1-8, Doshomachi 3-Chome, Chuo-ku, Osaka 541-0045, Japan
TEL +81-6-6209-6974
Email masaru.sawada@shionogi.co.jp

Public contact
Name of contact person
1st name Masakazu
Middle name
Last name Notohara
Organization Shionogi & Co., Ltd.
Division name Pharmacovigilance Department
Zip code 541-0045
Address 1-8, Doshomachi 3-Chome, Chuo-ku, Osaka 541-0045, Japan
TEL +81-6-6209-6958
Homepage URL
Email masakazu.notohara@shionogi.co.jp

Sponsor
Institute Shionogi & Co., Ltd.
Institute
Department

Funding Source
Organization Shionogi & Co., Ltd.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization N/A
Address N/A
Tel N/A
Email N/A

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2019 Year 10 Month 01 Day

Related information
URL releasing protocol
Publication of results Published

Result
URL related to results and publications https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa1622/5939856
Number of participants that the trial has enrolled 208225
Results please refer described below:
https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciaa1622/5939856
Results date posted
2021 Year 01 Month 20 Day
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Main results already published
Date of protocol fixation
2019 Year 09 Month 30 Day
Date of IRB
2019 Year 09 Month 30 Day
Anticipated trial start date
2019 Year 10 Month 07 Day
Last follow-up date
2020 Year 01 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information N/A

Management information
Registered date
2019 Year 09 Month 30 Day
Last modified on
2021 Year 01 Month 20 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043498

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.